Needham & Company Starts Sage Therapeutics (SAGE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures subdued as investors weigh earnings, oil prices
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
BofA/Merrill Lynch Starts Sage Therapeutics (SAGE) at Buy
May 12, 2017 7:36 AM EDTBofA/Merrill Lynch initiates coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $85.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $68.69 yesterday.
... More